Purchase any WEBINAR and get
10% Off
CODE: SAVE10
T&C applicable, please referFAQ
Validity : 14th Apr'24 to 24th Apr'24
Implications of Trump Administration for the FDA
- President Trump’s vow to overhaul the Food & Drug Administration
- Trump’s intentions to upend and streamline the drug approval process
- HHS Head Tom Price and past policies that he has supported as well as his intentions for HHS programs
- An analysis of Dr. Scott Gottlieb, Trump’s new pick to head the FDA
- Potential risks of deregulation for drugs and other FDA regulated products
- Industry reactions to Trump’s call to cut regulations
Overview of the webinar
President Donald Trump and his advisers have made it pretty clear that they would like to see big reforms in the U.S. Food and Drug Administration (FDA). Earlier, the complex regulations of the FDA have been blamed for getting in the way of drug innovation by making it difficult for new medicines to enter the market. Calls for softer regulations have been made to spur drug approvals and innovation.
Who should attend?
- Regulatory Directors
- Managers & Associates
- Compliance Managers
- Drug & Medical Device Marketing Managers
Why should you attend?
Will the Trump Administration be a game changer for the FDA? This event will explore the implications of the Trump Administration and President Trump’s pick of Tom Price as Secretary of Health & Human Services on the future of the FDA. The event will cover Trump’s deregulation task force at federal agencies and how his budget cuts may impact FDA. Trump’s new pick for commissioner of the FDA, Dr. Scott Gottlieb, will be discussed as well as his intention to ease drug and medical device regulations and streamline the agency and the drug approval process. This presentation will provide insight into what changes may be coming for the FDA and HHS.
Faculty - Ms.Norma Skolnik
Norma Skolnik has over 35 years of regulatory experience working with the pharmaceutical and dietary supplement industries. She served as Director of Regulatory Affairs for the Americas for Cadbury Adams. Prior to that she was Director of Regulatory Affairs for the Adams Division of Pfizer and Associate Director Of Regulatory Affairs for the Warner-Lambert company. She also served as Director of Regulatory Affairs for Lederle Consumer Healthcare and as Associate Director of Marketed Product Support for Lederle Laboratories and Associate Director of Regulatory Affairs for Wyeth.